Overview
Updated 14 Jul 2026
Kanwal P.S. Raghav, MD, is Professor, Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. The public record shows 528 publications with 9,173 citations (h-index 48), centered on Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Genetic factors in colorectal cancer. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 18 companies, 1 NIH-funded awards (2020–2024).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 114.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 2Not, yet, recruitingNCT07551596 - Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 2SuspendedNCT07071961 - A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
Sponsor: GlaxoSmithKline
InvestigatorPhase 1/PHASE2RecruitingNCT06885034
Industry payments
Updated 14 Jul 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202525 payments$18,976openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20251 payment
- Boehringer Ingelheim International GmbHProgram year20251 payment
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2024$546,557R01CA243554 - A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2023$559,111R01CA243554 - A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2022$554,559R01CA243554
Congress activity
Updated 14 Jul 2026
191 congress contributions (2011–2025) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- A retrospective analysis of taxane-based chemotherapy in small bowel adenocarcinoma (SBA).
ASCO Annual Meeting
ASCO2025Co-author - Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study.
ASCO Annual Meeting
ASCO2025Presenting author - Clinicopathologic features of complement activation signatures in colorectal cancer.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab.
Journal of the National Cancer Institute
2026 - Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.
Clinical cancer research
2026
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1515 Holcombe Blvd., Unit 426, Houston, TX 77030
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/kanwal-raghav-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Kanwal-Raghav
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/kanwal_raghav
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/mdandersoncancercenter_raghav-works-through-a-crc-patient-case-after-activity-6574441164286550016-edKb
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
thelancetoncology.buzzsprout.com/1391338/episodes/15623788-kanwal-raghav-on-trastuzumab-deruxtecan-in-her2-positive-advanced-colorectal-cancer-destiny-crc02
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thelancetoncology.buzzsprout.com ↗ - Other
onclive.com/authors/kanwal-raghav-md-mbbs-the-university-of-texas-md-anderson-cancer-center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
- 5,579
- publications
- 233
- h-index
- 24
- trials
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
- 1,905
- publications
- 187
- h-index
- 1
- trial
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
- 2,643
- publications
- 148
- h-index
- 8
- trials